TY - CHAP A1 - De Witt Huberts, Jessie A1 - Wernicke, Sarah A1 - Wippert, Pia-Maria T1 - The pain of being misunderstood: The impact of invalidation on pain sensation in chronic back pain patients T2 - Psychosomatic medicine Y1 - 2014 SN - 0033-3174 SN - 1534-7796 VL - 76 IS - 3 SP - A113 EP - A114 PB - Lippincott Williams & Wilkins CY - Philadelphia ER - TY - GEN A1 - Wernicke, Sarah A1 - De Witt Huberts, Jessie A1 - Wippert, Pia-Maria T1 - The pain of being misunderstood BT - invalidation of pain complaints in chronic low back pain patients T2 - Postprints der Universität Potsdam : Humanwissenschaftliche Reihe N2 - A particular form of social pain is invalidation. Therefore, this study (a) investigates whether patients with chronic low back pain experience invalidation, (b) if it has an influence on their pain, and (c) explores whether various social sources (e.g. partner and work) influence physical pain differentially. A total of 92 patients completed questionnaires, and for analysis, Pearson's correlation coefficients and hierarchical linear regression analyses were conducted. They indicated a significant association between discounting and disability due to pain (respective =.29, p>.05). Especially, discounting by partner was linked to higher disability (=.28, p>.05). T3 - Zweitveröffentlichungen der Universität Potsdam : Humanwissenschaftliche Reihe - 403 KW - chronic low back pain KW - disability KW - invalidation KW - social pain KW - social rejection Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-404864 IS - 403 ER - TY - JOUR A1 - Wernicke, Sarah A1 - de Witt Huberts, Jessie A1 - Wippert, Pia-Maria T1 - The pain of being misunderstood BT - Invalidation of pain complaints in chronic low back pain patients JF - Journal of Health Psychology N2 - A particular form of social pain is invalidation. Therefore, this study (a) investigates whether patients with chronic low back pain experience invalidation, (b) if it has an influence on their pain, and (c) explores whether various social sources (e.g. partner and work) influence physical pain differentially. A total of 92 patients completed questionnaires, and for analysis, Pearson’s correlation coefficients and hierarchical linear regression analyses were conducted. They indicated a significant association between discounting and disability due to pain (respective β = .29, p > .05). Especially, discounting by partner was linked to higher disability (β = .28, p > .05). KW - chronic low back pain KW - disability KW - invalidation KW - social pain KW - social rejection Y1 - 2017 U6 - https://doi.org/10.1177/1359105315596371 SN - 1359-1053 SN - 1461-7277 VL - 22 SP - 135 EP - 147 PB - Sage Publ. CY - London ER - TY - CHAP A1 - Wernicke, Sarah A1 - Carlsohn, Anja A1 - Heydenreich, Juliane A1 - Mayer, Frank T1 - Does the copenhagen soccer test induce a repeated bout effect? - a pilot study T2 - Medicine and science in sports and exercise : official journal of the American College of Sports Medicine Y1 - 2013 SN - 0195-9131 SN - 1530-0315 VL - 45 IS - 5 SP - 169 EP - 169 PB - Lippincott Williams & Wilkins CY - Philadelphia ER - TY - JOUR A1 - Rüther, Ferenc Darius A1 - Sebode, Marcial A1 - Lohse, Ansgar W. A1 - Wernicke, Sarah A1 - Böttinger, Erwin A1 - Casar, Christian A1 - Braun, Felix A1 - Schramm, Christoph T1 - Mobile app requirements for patients with rare liver diseases BT - a single center survey for the ERN RARE-LIVER JF - Clinics and research in hepatology and gastroenterology N2 - Background: More patient data are needed to improve research on rare liver diseases. Mobile health apps enable an exhaustive data collection. Therefore, the European Reference Network on Hepatological diseases (ERN RARE-LIVER) intends to implement an app for patients with rare liver diseases communicating with a patient registry, but little is known about which features patients and their healthcare providers regard as being useful. Aims: This study aimed to investigate how an app for rare liver diseases would be accepted, and to find out which features are considered useful. Methods: An anonymous survey was conducted on adult patients with rare liver diseases at a single academic, tertiary care outpatient-service. Additionally, medical experts of the ERN working group on autoimmune hepatitis were invited to participate in an online survey. Results: In total, the responses from 100 patients with autoimmune (n = 90) or other rare (n = 10) liver diseases and 32 experts were analyzed. Patients were convinced to use a disease specific app (80%) and expected some benefit to their health (78%) but responses differed signifi-cantly between younger and older patients (93% vs. 62%, p < 0.001; 88% vs. 64%, p < 0.01). Comparing patients' and experts' feedback, patients more often expected a simplified healthcare pathway (e.g. 89% vs. 59% (p < 0.001) wanted access to one's own medical records), while healthcare providers saw the benefit mainly in improving compliance and treatment outcome (e.g. 93% vs. 31% (p < 0.001) and 70% vs. 21% (p < 0.001) expected the app to reduce mistakes in taking medication and improve quality of life, respectively). KW - Primary sclerosing cholangitis KW - Primary biliary cholangitis KW - Autoimmune KW - hepatitis KW - European reference networks KW - Mobile applications KW - Patient KW - reported out-come measures Y1 - 2021 U6 - https://doi.org/10.1016/j.clinre.2021.101760 SN - 2210-7401 SN - 2210-741X VL - 45 IS - 6 PB - Elsevier Masson CY - Amsterdam ER - TY - GEN A1 - Konigorski, Stefan A1 - Wernicke, Sarah A1 - Slosarek, Tamara A1 - Zenner, Alexander Maximilian A1 - Strelow, Nils A1 - Ruether, Darius Ferenc A1 - Henschel, Florian A1 - Manaswini, Manisha A1 - Pottbäcker, Fabian A1 - Edelman, Jonathan Antonio A1 - Owoyele, Babajide A1 - Danieletto, Matteo A1 - Golden, Eddye A1 - Zweig, Micol A1 - Nadkarni, Girish N. A1 - Bottinger, Erwin T1 - StudyU: A Platform for Designing and Conducting Innovative Digital N-of-1 Trials T2 - Zweitveröffentlichungen der Universität Potsdam : Reihe der Digital Engineering Fakultät N2 - N-of-1 trials are the gold standard study design to evaluate individual treatment effects and derive personalized treatment strategies. Digital tools have the potential to initiate a new era of N-of-1 trials in terms of scale and scope, but fully functional platforms are not yet available. Here, we present the open source StudyU platform, which includes the StudyU Designer and StudyU app. With the StudyU Designer, scientists are given a collaborative web application to digitally specify, publish, and conduct N-of-1 trials. The StudyU app is a smartphone app with innovative user-centric elements for participants to partake in trials published through the StudyU Designer to assess the effects of different interventions on their health. Thereby, the StudyU platform allows clinicians and researchers worldwide to easily design and conduct digital N-of-1 trials in a safe manner. We envision that StudyU can change the landscape of personalized treatments both for patients and healthy individuals, democratize and personalize evidence generation for self-optimization and medicine, and can be integrated in clinical practice. T3 - Zweitveröffentlichungen der Universität Potsdam : Reihe der Digital Engineering Fakultät - 12 KW - digital interventions KW - N-of-1 trial KW - SCED KW - single-case experimental design KW - web application KW - mobile application KW - app KW - digital health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-580370 IS - 12 ER - TY - JOUR A1 - Konigorski, Stefan A1 - Wernicke, Sarah A1 - Slosarek, Tamara A1 - Zenner, Alexander Maximilian A1 - Strelow, Nils A1 - Ruether, Darius Ferenc Ruether A1 - Henschel, Florian A1 - Manaswini, Manisha A1 - Pottbäcker, Fabian A1 - Edelman, Jonathan Antonio A1 - Owoyele, Babajide A1 - Danieletto, Matteo A1 - Golden, Eddye A1 - Zweig, Micol A1 - Nadkarni, Girish N. A1 - Bottinger, Erwin T1 - StudyU: A Platform for Designing and Conducting Innovative Digital N-of-1 Trials JF - Journal of Medical Internet Research N2 - N-of-1 trials are the gold standard study design to evaluate individual treatment effects and derive personalized treatment strategies. Digital tools have the potential to initiate a new era of N-of-1 trials in terms of scale and scope, but fully functional platforms are not yet available. Here, we present the open source StudyU platform, which includes the StudyU Designer and StudyU app. With the StudyU Designer, scientists are given a collaborative web application to digitally specify, publish, and conduct N-of-1 trials. The StudyU app is a smartphone app with innovative user-centric elements for participants to partake in trials published through the StudyU Designer to assess the effects of different interventions on their health. Thereby, the StudyU platform allows clinicians and researchers worldwide to easily design and conduct digital N-of-1 trials in a safe manner. We envision that StudyU can change the landscape of personalized treatments both for patients and healthy individuals, democratize and personalize evidence generation for self-optimization and medicine, and can be integrated in clinical practice. KW - digital interventions KW - N-of-1 trial KW - SCED KW - single-case experimental design KW - web application KW - mobile application KW - app KW - digital health Y1 - 2021 U6 - https://doi.org/10.2196/35884 SN - 1438-8871 VL - 24 PB - JMIR Publications CY - Richmond, Virginia, USA ET - 7 ER - TY - JOUR A1 - Konigorski, Stefan A1 - Wernicke, Sarah A1 - Slosarek, Tamara A1 - Zenner, Alexander M. A1 - Strelow, Nils A1 - Ruether, Darius F. A1 - Henschel, Florian A1 - Manaswini, Manisha A1 - Pottbäcker, Fabian A1 - Edelman, Jonathan A. A1 - Owoyele, Babajide A1 - Danieletto, Matteo A1 - Golden, Eddye A1 - Zweig, Micol A1 - Nadkarni, Girish N. A1 - Böttinger, Erwin T1 - StudyU: a platform for designing and conducting innovative digital N-of-1 trials JF - Journal of medical internet research N2 - N-of-1 trials are the gold standard study design to evaluate individual treatment effects and derive personalized treatment strategies. Digital tools have the potential to initiate a new era of N-of-1 trials in terms of scale and scope, but fully functional platforms are not yet available. Here, we present the open source StudyU platform, which includes the StudyU Designer and StudyU app. With the StudyU Designer, scientists are given a collaborative web application to digitally specify, publish, and conduct N-of-1 trials. The StudyU app is a smartphone app with innovative user-centric elements for participants to partake in trials published through the StudyU Designer to assess the effects of different interventions on their health. Thereby, the StudyU platform allows clinicians and researchers worldwide to easily design and conduct digital N-of-1 trials in a safe manner. We envision that StudyU can change the landscape of personalized treatments both for patients and healthy individuals, democratize and personalize evidence generation for self-optimization and medicine, and can be integrated in clinical practice. KW - digital interventions KW - N-of-1 trial KW - SCED KW - single-case experimental design KW - web application KW - mobile application KW - app KW - digital health Y1 - 2022 U6 - https://doi.org/10.2196/35884 SN - 1439-4456 SN - 1438-8871 VL - 24 IS - 7 PB - Healthcare World CY - Richmond, Va. ER -